gaitQ

gaitQ operates at the intersection of neurological medical devices, digital health, and assistive wearables, with a focused application in Parkinson’s disease rather than a broad consumer fitness market. Its principal differentiation is the gaitQ tempo™ system: a non-invasive, bilateral wearable that uses personalized rhythmic cueing to address freezing of gait, an underserved symptom associated with instability and falls. The company combines patient-led design with engineering, physiology, signal processing, and wearable-device expertise, including real-time computation of gait characteristics and wavelet-based signal processing. Relative to general gait-monitoring platforms, gaitQ appears more intervention-oriented: it aims not only to measure mobility but also to provide tactile prompts during walking. Its Oxford origins, clinical framing, and research collaboration with machineMD support credibility in healthcare settings, while its small estimated employee band of 11–50 indicates an early commercial and operational scale. The company’s competitive position therefore depends on clinical validation, regulatory progress, reimbursement, and the ability to translate a specialized Parkinson’s use case into sustained healthcare adoption.

gaitQ shows a progression from Oxford-originated venture formation to targeted clinical and market validation. The company was founded in 2019, with Dongli Li joining as Co-Founder and CPO in October 2019 and William Collins becoming CEO in November 2019. It recorded a £1.5 million seed round on Sep 8, 2020, equivalent to $1,944,804 in the available financial record, with Parkwalk Advisors as the identified investor. A separate February 2021 pre-seed financing of £625,000, approximately $810,335 using the available GBP-to-USD conversion, is also associated with the company, although it is not reflected in the structured two-round total. The 2024 grant involving Innosuisse and Innovate UK marked a shift toward externally supported research and international Parkinson’s monitoring work. Coverage of the associated project cited approximately $1 million in funding and machineMD as a collaborator. The July 2024 PITCH@Med-Tech Innovation Expo win provided additional validation. Growth remains difficult to quantify because hiring data, revenue, regulatory milestones, and commercialization metrics are limited. The clearest inflection points are the launch and development of gaitQ tempo™, the 2020 seed financing, the 2021 pre-seed financing, and the 2024 research grant.